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ABSTRACT
Objective: The prevalence of hepatitis B and hepatitis C in a sexually transmitted disease (STD)
clinic population was studied, along with the prevalence of various STD agents, in an attempt to
identify possible STD markers for the hepatitis C virus and help delineate the role of hepatitis C as
an STD. The hepatitis C antibody rates found in the STD clinic were also compared with those
found among patients attending a localOB/GYN clinic and those enrolled in a blood donor program,
all from the same geographical area.
Methods:A total of 150 women attending an STD clinc were examined for each of the following
agents: Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, hepatitis B surface antigen, hepatitis
B core antibody, hepatitis B surface antibody, and hepatitis C virus antibody. Additionally, several
patients who signed informed consent to be evaluated for human immunodeficiency virus (HIV)
antibody were tested by an enzyme immunoassay (EIA) screen method. The prevalence of each
agent was then compared with the other agents.
Results: The overall prevalence rates detected were as follows: hepatitis B 16%, hepatitis C 4%,
chlamydia 18.7%, gonorrhea 7.4%, syphilis 0.7%, andHIV 0%. HepatitisC antibody was detected in
4% of patients in the STD clinic, 0.76% of volunteer blood donors from central Pennsylvania, and
0% ofpatients studied from the Harrisburg Hospital (Harrisburg, PA) prenatal population.
Conclusions: This screening study reveals an association between attending a Harrisburg, PA,
area STD clinic and having an increased prevalence of hepatitis C antibody, but larger matched
control studies will be needed to help clarify sexual transmission as a mode of transmission for the
hepatitisC virus. (C) 1994 Wiley-Liss, Inc.
KEY WORDS
Incidence, non-A, non-B hepatitis, STD
hepatitis is reported in 10-20%
of patients receiving 3 or more units of blood.
Many patients who contract hepatitis have no de-
tectable antibody against type A or B hepatitis vi-
ruses and are classified as having non-A, non-B
hepatitis. Ninety percent of" post-transfusion hepa-
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titis has now been attributed to non-A, non-B hepa-
titis worldwide.
1,2 However, this type of transmis-
sion was recently estimated to account for as low as
only 10-15% of patients with non-A, non-B hepa-
titis.
3 Recently, the isolation and cloning of a piece
of DNA from non-A, non-B hepatitis virus and
development of an assay for the antibody to hepati-
tis C virus (HCV) made possible the detection of
many patients with a non-A, non-B hepatitis and
the examination oftransmission routes. 4’5 Recently,
a 2nd-generation test for the detection of antibody
vs. HCV was licensed.
6 This 2nd-generation test
offers the advantage of increased sensitivity and
specificity for the determination of HCV anti-
body. s’6 Results have suggested that HCV is the
major cause of transfusion-related non-A, non-B
hepatitis,
7 especially in those cases that develop
chronicity.
8 Additionally, HCV appears to be the
major cause of a number of community-acquired
non-A, non-B hepatitis for which no history of
percutaneous exposure has been identified.
1,2,9
Studies investigating the possible sources of in-
fection for non-A, non-B hepatitis or I-ICV without
a history of percutaneous exposure have been con-
tradictory to date. Several small case reports have
been published recognizing possible transmission
due to perinatal and conjugal relationships that fol-
low patterns similar to transmission of hepatitis B,
human immunodeficiency virus (HIV), and hu-
man T-lymphotropic virus type I (HTLV 1).
10,11
In addition, other papers including studies relating
HCV to patients with sexually transmitted diseases
(STDs)6’12 and to heterosexual activity with more
than partner have been published.
13 Contrary to
these findings, other investigations have suggested
only rare sexual transmission of HCV among ho-
mosexuals
3 and among sexual contacts of high-risk
intravenous (IV)-drug abusers.
2
To further delineate the possible method of
spread for HCV, we studied the prevalence of hep-
atitis B infection and hepatitis C infection in an
STD clinic population and correlated other known
STDs as possible markers for patients at high risk
for hepatitis B and hepatitis C.
SUBJECTS AND METHODS
Subjects
Women attending a Harrisburg area STD clinic
were included in the study if they signed informed
TABLE I. Demographic and clinical information
collected on STD patients
Today’s date: Age:
I. Race (circle one):
Black White Hispanic Asian Other
2. Did you have a blood transfusion (received
blood) between 1979 and May 1985?
3. Has there been any one year since 1980 during
which you had more than 5 partners?
4. In the past 9 years, have you had sex with a
person who was
A. an IV drug abuser
B. a hemophiliac
C. a bisexual
D. a prostitute
5. Have you ever had sex with anyone who (to
your knowledge) had AIDS or was infected with
the AIDS virus?
6. Have you ever had any of the following STDs?
Gonorrhea
Herpes
Chlamydia
Syphilis
Genital warts
Pelvic inflammatory disease
7. In the past 9 years, have you used IV drugs?
8. Have you ever had sex in exchange for money or
drugs?
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
consent and completed a questionnaire assessing
their risk factors (Table 1). Black, Caucasian, and
Hispanic individuals were included in the study.
The prevalence of hepatitis C in the central Penn-
sylvania blood donor population and the Harris-
burg Hospital prenatal population was also evalu-
ated.
Laboratory Methods
Chlamydia trachornatis
Two direct antigen tests (enzyme immunoassay
[EIA] methods, Chlamydiazyme, Abbott Labora-
tories, Abbott Park, IL, and a research membrane
filtration technique, Seradyn, Inc., Indianapolis,
IN) and culture were performed on the specimens
collected from the patients for the diagnosis of in-
fection with C. trachomatis. In addition, the culture
transport fluid was analyzed by direct immunoflu-
orescence (DFA) for the presence of C. trachomatis
antigen as previously described.
14 A specimen was
considered positive for C. trachomatis if the culture
was positive or if 2 of the 3 direct antigen tests were
positive. All chlamydial procedures were performed
according to the manufacturers’ specifications.
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TABLE 2. Percentage of patients exhibiting multiple
risk factors
Total number of risk factors
0 35
37
2 17
3 6
4 4
5 0
6
Total 100
Hepatitis B Testing
Auszyme, hepatitis BsAg (HBsAg), Corzyme, anti-
hepatitis B core antigen (anti-HBc), and Ausab,
anti-hepatitis Bs antigen (anti-HBs; Abbott Labo-
ratories) were performed according to the manufac-
turer’s specifications. Only those specimens that
were repeatedly reactive were classified positive.
For statistical analysis, those patients who exhibited
or all of the above markers without history of
vaccination were considered to have evidence of
hepatitis B infection at some time in the past.
Hepatitis C Testing
The presence of serum HCV (anti-HCV; Abbott
Laboratories) antibody was measured according to
the manufacturer’s specifications. Both st- and
2nd-generation tests for the detection of antibody
vs. HCV were used. Each reactive result was con-
firmed in duplicate and sent for confirmatory test-
ing. The confirmatory test performed was the Chi-
ron HCV recombinant immunoblot assay (RIBA;
Chiron Corporation, Berkeley, CA).
Bacterial Culture and Syphilis Serology
Gonococcal cultures were performed on Martin
Lewis agar medium in a 5% carbon dioxide atmo-
sphere. Standard bacteriologic techniques were used
to identify the isolates.
15 Syphilis serology utilized
16 a standard Rapid Plasma Reagin (RPR) assay.
Statistical Analysis
The goal of our analyses was to determine whether
there was a significant association between the
STDs, i.e., whether presence of STD increased
the chance of having another. Thus, every pair of
STDs was tested for association using the Fisher-
Irwin exact test (Table 2).
17 To determine whether
the observed associations would hold up after con-
TABLE 3. Total number of patients categorized by
questionnaire and chart review for demographic
data and risk characteristics
Race
Hispanic 4
Caucasian 49
Black 46
Asian 0
Other
Total 100
Age (years)
13-20 45
21-30 37
31-40 14
41-50 3
51-54
Total 100
High-risk sexual practices
Multiple sex partners 17
With IV-drug user 10
With hemophiliac 0
With bisexual 4
With prostitute
With someone having AIDS
For money or drugs 2
Previous medical conditions
Blood transfusion 2
Gonorrhea 19
Syphilis 3
Herpes 3
Genital warts 19
Chlamydia 23
Pelvic inflammatory disease 6
trolling for STD risk status, we classified the
women into high-risk and low-risk strata, then car-
ried out a stratified analysis using the Cochran-
Mantel-Haenszel (CMH) test.
18 We determined
risk status by questionnaire and chart review (Table
3). Using these criteria, we called subjects "low
risk" if they had no known behavioral or medical
risk factors and classified those subjects with any
risk factors as "high risk." Most computations were
executed in the S-Plus language on a Sun SPARC-
station workstation.
19 Exact tests were computed
with StatXact, version 2.0 (Cytel, Cambridge, MA).
RESULTS
Demographic information on patients seen at the
Harrisburg area STD clinic is presented in Table
3. Subjects ranged in age from 13 to 54 years. The
most frequent risk factors are presented as percent-
ages in Table 3 and by prevalence in Table 2. The
most prevalent risk factor was multiple sexual part-
ners26 (17%), followed by sex with an IV-drug
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TABLE 4. Prevalence rates of 6 STDs with P values for tests of association
a
Disease P value from test of association
(prevalence) Hepatitis C Chlamydia Gonorrhea Syphilis HIV
Hepatitis B (I 6.0%) 0.052 0.701 0.557 0.327 ND
Hepatitis C (4.0%) 0.717 0.063 0.082 ND
Chlamydia (I 8.7%) 0.034 0.189 ND
Gonorrhea (7.4%) 0.151 ND
Syphilis (0.7%) ND
HV (0%)
ap values are from I-sided Fisher exact tests of the hypothesis of no association between the diseases against the alternative of positive association. ND
indicates insufficient data to test the hypothesis. Sample sizes are 149 for gonorrhea, 148 for syphilis, 27 for HI, and 150 for hepatitis B and C and
chlamydia.
abuser--15 (10%). Thirty-five patients admitted
to having had a chlamydial infection at some time
in the past. There were 53 "low-risk" and 97 "high-
risk" subjects as defined in the previous section.
Prevalence rates of 6 STDs are presented in Table
4. When the 1-sided Fisher-Irwin test was per-
formed, associations between chlamydia and gonor-
rhea (P 0.034) and between hepatitis B and
hepatitis C (P 0.052) were found. After stratifi-
cation using the CMH test, the chlamydia/
gonorrhea test (P 0.052) and the hepatitis
B/hepatitis C test (P 0.086) approach significant
positive associations. These results support conclu-
sions reached using the Fisher-Irwin test mentioned
earlier. The only statistically significant association
following stratification was found between hepatitis
C and syphilis (P 0.044). However, the associ-
ation between these 2 diseases was negative.
Seven patients were found to be repeatedly reac-
tive by the HCV EIA procedure. Six of the 7
(85.7%) reactive EIA specimens were found to be
positive for antibody to HCV by the 2nd-genera-
tion HCV (EIA) procedure and by the RIBA. Of
these 6 patients, 3 were also positive for hepatitis B
core antibody. Of the subjects who were confirmed
positive for HCV antibody, only (16%) had no
risk factor as defined earlier. Three or 50% of the
HCV-positive subjects had multiple risk factors
with the most common risk factors being previous
blood transfusion (50%), IV-drug abuse (33%),
and multiple sexual partners (33%). No statistically
significant associations were found for HCV-posi-
tive subjects and their risk factors. Other STDs
were detected in those patients positive for HCV;
however, no statistically significant association was
determined. The overall prevalence of hepatitis C
in 3 populations (STD, prenatal, and blood donor)
TABLE 5. Comparison of hepatitis C antibody in 3
Harrisburg patient populations
a
Population studied Prevalence
STD clinic 6/150 (4%)
Blood donor 59/7,744 (0.76%)
Prenatal 0/100 (0%)
aAII positive HCV antibody tests were confirmed by RIBA.
is presented in Table 5. They are significantly dif-
ferent by the exact test on the 3 x 2 table
(P 0.0005). Pairwise differences are significant
for STD clinic vs. blood donor (P 0.0012) and
STD clinic vs. prenatal (P 0.04). The blood
donor and the prenatal groups are not significantly
different.
DISCUSSION
HCV has been shown to be the causative agent of
the majority of cases of post-transfusion hepati-
tis,
1,20,). especially high-risk transfusion patients
such as hemophiliacs,
22-24 chronic renal patients,
and those patients with recent cardiac surgery.
24 In
addition, the agent has been found in U.S. veter-
ans,
2s and implicated in maternal transmission,
11,26
sexual transmission,
12,13,27 and IV-drug abuse. 28’29
The purpose of the present study was to explore the
relationships between STDs and current or prior
HCV infection and thus identify known STDs as
possible markers for HCV. To discriminate the
prevalence of HCV in the high-risk groups from
that in the normal population, we studied the prev-
alence of I--ICV in 2 low-risk patient populations in
the Harrisburg area.
Positive associations between STDs were found
in the 150 STD patients studied. As expected, pa-
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tients positive for C. trachomatis were likely to be
infected with N. gonorrhoeae. We also found hepa-
titis B virus (HBV) and HCV to be associated with
one another. The presence of hepatitis B markers
(anti-HBc, anti-HBe, HBeAg) has been related to
the presence of I-ICV in blood donors and chronic
HCV carriers. 3’31 However, significant debate
continues on the reliability of surrogate markers in
blood donor populations for predicting the pres-
ence ofHCV.
32-34
HBV and HCV seem to be transmitted concom-
itantly in the United States and most of Europe,
while Japan and selected countries in Europe show
little or no association between transmission of I--IBV
and I-ICV. Differences in these associations could
possibly be due to some unknown risk factors that
are found in certain geographical locales and not in
others. It has been suggested that several classes of
HCV exist, with varying subtypes more prevalent
in different countries. Geographical and/or genetic
differences have yet to be explored as a method for
interpreting transmission routes and prevalence
rates. Studies have also suggested that heterosexual
promiscuity and/or homosexual promiscuity with
evidence of numerous prior STDs constitute sig-
nificant risk factors for the transmission of both
HBV and HCV. 12’13’27 Considerable debate over
the role sexual practices have on the transmission of
HCV can be found in the current literature. 3’9
In the present study, antibody to HCV was de-
tected in 4% of patients attending a Harrisburg
area STD clinic, in 0.76% of volunteer blood do-
nors from central Pennsylvania, and in none of the
patients studied from Harrisburg Hospital’s pre-
natal population. Hess et al.
9 found similar results
with 4.7% and 0.51% positive anti-HCV results
from STD and blood donor patients, respectively.
Additional studies in the current literature have
shown that the positive rates for I--ICV in blood
donors range between 0.5 and 1.5%
1,21,34,35 Posi-
tive rates for sexual transmission of non-A, non-B
hepatitis in heterosexual and homosexual popula-
tions have ranged between 4.7 and 50%. 9’12’13’27’35
Additional risk factors have included race, nation-
ality, sex of the patient, multiple sexual partners,
IV-drug abuse, preyious or concurrent positive tests
forHBV and HIV, and evidence ofmultiple STDs.
Our data differ slightly from a recently published
review by Lynch-Salamon and Combs.
35 The inci-
dence reported in their review of the literature
agrees with our data for blood donors and for those
patients attending an STD clinic. However, the
incidence ofHCV positivity by risk groups in our
study is lower than that previously reported.
35 This
is undoubtedly due to the small number of HCV-
positive patients found in the Harrisburg area STD
clinic. The present study shows that attending a
Harrisburg area STD clinic is associated with an
increased prevalence of I--ICV compared with 2
other low-risk populations in the same geographical
area. However, we were unable to identify any
specific disease among the known STDs that corre-
lated statistically with the presence ofHCV for use
as a marker for HCV infection. Additional larger
studies involving matched controls would be help-
ful in order to help clarify the mode oftransmission
ofHCV.
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